英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • Jakafi - Polycythemia Vera, Myelofibrosis, Acute Chronic . . .
    Learn about Jakafi® (ruxolitinib) – Used to treat adults with polycythemia vera who have taken hydroxyurea and it did not work well enough or they could not tolerate it, and adults with certain types of myelofibrosis
  • Ruxolitinib - Wikipedia
    Ruxolitinib is a Janus kinase inhibitor [5] It was developed and marketed by Incyte Corp in the US under the brand name Jakafi, [5] and by Novartis elsewhere in the world, under the brand name Jakavi [13] It was approved for medical use in the United States in 2011, [14] and in the European Union in 2012 [7]
  • Patient Assistance Program | IncyteCARES
    Find an IncyteCARES patient assistance program for eligible patients taking Incyte medications
  • Jakafi® (ruxolitinib) | Official Healthcare Professional Website
    Jakafi ® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults
  • Generic Jakafi Availability - Drugs. com
    Generic Jakafi Availability Last updated on Jun 11, 2025 Jakafi is a brand name of ruxolitinib, approved by the FDA in the following formulation(s): JAKAFI (ruxolitinib phosphate - tablet;oral) Manufacturer: INCYTE CORP Approval date: November 16, 2011
  • Your Guide to Jakafi for Polycythemia Vera: What You . . . - WebMD
    Jakafi (ruxolitinib) is a prescription medicine for people with certain types of polycythemia vera (PV) It is not chemotherapy In 2014, it was approved for people with PV who did not respond
  • Jakafi by Incyte Corporation - Pharmacy Times
    Jakafi (ruxolitinib) is the first drug approved by the FDA for the treatment of the chronic bone marrow disease polycythemia vera
  • JAKAVI® (ruxolitinib) | HCP
    JAKAVI® (ruxolitinib) for the treatment of myelofibrosis and for the treatment of polycythaemia vera in patients resistant to or intolerant of hydroxyurea


















中文字典-英文字典  2005-2009